Earnings call transcript: Veeva Systems Q1 2026 earnings beat expectations, stock surges

Veeva Systems (VEEV) reported a strong Q1 FY2026, exceeding expectations with EPS of $1.97 versus the $1.74 forecast and revenue of $759 million compared to the expected $728.32 million, leading to a 15.46% surge in aftermarket trading to $270.75. The company's performance was driven by Veeva.ai and Vault CRM, as well as continued growth in the Crossix segment, prompting Veeva to raise its billings guidance for the year. Despite macroeconomic uncertainties, Veeva remains optimistic, targeting further expansion of Vault CRM and exploring AI licensing revenue, with CEO Peter Gassner emphasizing the company's commitment to AI innovation.

Analysis

Veeva Systems Inc. (VEEV) reported a robust first quarter for fiscal year 2026, significantly outperforming analyst expectations. The company announced earnings per share (EPS) of $1.97, substantially above the forecasted $1.74, and revenue of $759 million, exceeding the anticipated $728.32 million. This performance represents a 13.2% EPS surprise and a 4.2% revenue beat. Key growth drivers included strong momentum in its Veeva.ai initiatives and Vault CRM, which now has over 80 customers live and is on track for 200 within the next year, with approximately half of new Vault CRM customers being net new to Veeva. The Crossix segment also demonstrated notable strength, particularly in digital marketing measurement, contributing to a revenue growth rate of 16.2% for the company and growing over 30% year-over-year itself. Financially, Veeva maintains a strong position, evidenced by an InvestingPro "GREAT" overall health score, a gross profit margin of 74.5%, a current ratio of 4.51, a 46% non-GAAP operating margin, and a zero debt-to-capital ratio. The company has achieved its $3 billion revenue run rate goal for calendar 2025 and subsequently raised its billings guidance for the current fiscal year. CEO Peter Gassner highlighted a strong commitment to AI, aiming to enhance life sciences efficiency by 15% by 2030. Veeva is also venturing into horizontal CRM, with plans to secure initial customers by the end of the year. Despite this positive outlook, management acknowledged increased macroeconomic uncertainties compared to 90 days prior, citing potential impacts from drug launch delays, FDA approval processes, and funding challenges for small biotechs, although no material impact has been observed in financial results or pipeline to date. The stock reacted favorably to the earnings, surging 15.46% in aftermarket trading to $270.75, surpassing its 52-week high of $258.93.

Key Decisions for Investors

• Investors should recognize Veeva's strong Q1 FY2026 performance, marked by significant EPS and revenue beats and a 15.46% aftermarket stock surge, as indicative of solid operational execution and continued market demand, particularly for its Crossix and Vault CRM solutions.
• Consider the raised full-year billings guidance as a sign of management's confidence, but weigh this against the acknowledged macroeconomic uncertainties, including potential FDA approval delays and biotech funding constraints, which could present headwinds despite not yet materializing.
• Monitor the progress of Veeva.ai and the strategic expansion into horizontal CRM as potential long-term growth catalysts, noting CEO Peter Gassner's ambition for AI to drive significant industry efficiency and the target for initial horizontal CRM customers by year-end.
• Evaluate the current valuation following the stock's recent appreciation, considering InvestingPro's assessment of the stock trading near Fair Value and analyst price targets ranging from $201 to $290, while acknowledging the company's robust fundamentals including a 74.5% gross profit margin and zero debt.